Manish led SeQuent since 2014 and played a major role in transforming the company
Jagsonpal Pharmaceuticals Limited announced the appointment of Manish Gupta as the Managing Director of the company.
Manish has a well-established track record of successfully leading and managing businesses across the globe. His last stint was with SeQuent Scientific Limited (SeQuent) as the CEO and Managing Director for 8 years. Previously, he has been the CEO - Pharma Business for Strides Pharma Science. Earlier, he was associated with Wockhardt in various capacities, his last role being the Managing Director of Pinewood Healthcare, Ireland and CEO of Radiant Research, a CRO in USA.
Manish led SeQuent since 2014 and played a major role in transforming the company from a small India-focused business to a global organization with operations in India, Turkey, Brazil and the EU, emerging as India's largest and 'Top 20' global animal health company. He undertook a series of structural moves including inorganic initiatives with emphasis on consolidating market presence, entering new markets and strengthening customer-centricity.
Rajpal Singh Kochhar, Founder and the incumbent Managing Director who led Jagsonpal since inception has stepped down. Kochhar and family will continue to be a part of the Promoter Group of the company.
Commenting on the development, Kochhar stated "While it's a difficult decision and moment to pass on the mantle of a business which we built from scratch over decades, I am happy that we have found the right partners to take the Company to the next level with a strong focus on growth and profitability. I take this opportunity to thank each and every one at Jagsonpal and in particular the Directors for their commitment. I wish Manish the very best and looking forward to see Jagsonpal delivering greater value to all stakeholders."
On the new role, Manish stated that "I am excited to take up the mantle to lead Jagsonpal, which I believe has a great business model and talented team. I look forward to work closely with the new Board to build on the great foundation laid by Rajpal Singh Kochhar, with a focus on growth and profitability."
Pfizer’s phase 3 studies of novel antibiotic combination offer new hope for patients with multidrug-resistant infections and treatment options
Merck partners with California-based research group to study catalysis innovation through machine learning
Philips and Masimo introduce advanced monitoring capabilities to Philips high acuity patient monitors
Subscribe To Our Newsletter & Stay Updated